Last reviewed · How we verify
NCT00829205
A Phase I/II Study of Methylselenocysteine (MSC) in Combination With Immunochemotherapy (R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 1/Phase 2 trial testing filgrastim in Lymphoma. Withdrawn.
Quick facts
| Lead sponsor | Cancer Research UK |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 January 2009 |
| Sites | 5 locations across United Kingdom |
Drugs / interventions tested
- filgrastim
- rituximab — full drug profile →
- Se-methyl-seleno-L-cysteine
- carboplatin (Carboplatin) — full drug profile →
- etoposide (etoposide) — full drug profile →
- ifosfamide
- laboratory biomarker analysis
- pharmacological study — full drug profile →
Conditions studied
- Lymphoma — all drugs for Lymphoma →
Sponsor
Cancer Research UK — full company profile →
Who can join
18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
- Dose-limiting toxicity and maximum tolerated dose of Se-methyl-seleno-L-cysteine (MSC) (Phase I)
- Overall response rate (Phase II)
Sponsor's own description
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer cell-killing substances to them. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Se-methyl-seleno-l-cysteine may help reduce the side effects of chemotherapy. PURPOSE: This phase I/II trial is studying the side effects and best dose of Se-methyl-seleno-l-cysteine when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well it works in treating patients with diffuse large B-cell lymphoma that has relapsed or not responded to treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Selenium Compounds as Novel Potential Anticancer Agents.
Radomska D, Czarnomysy R, Radomski D, Bielawski K. · · 2021 · cited 97× · PMID 33498364 · DOI 10.3390/ijms22031009 -
Selenium-Containing Agents Acting on Cancer-A New Hope?
Garbo S, Di Giacomo S, Łażewska D, Honkisz-Orzechowska E, et al · · 2022 · cited 29× · PMID 36678733 · DOI 10.3390/pharmaceutics15010104 -
Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer.
Zhong S, Jeong JH, Huang C, Chen X, et al · · 2021 · cited 21× · PMID 34587977 · DOI 10.1186/s13046-021-02109-z
Verify or expand the search:
- PubMed search for NCT00829205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of filgrastim
Trials testing the same drug.
- NCT06926751 — Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors · Phase 2 · not yet recruiting
- NCT04023669 — Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Re · Phase 1 · completed
- NCT03434262 — SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children · Phase 1 · completed
- NCT02029638 — BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance · Phase 2 · terminated
- NCT01707004 — Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients · Phase 2 · completed
Other recruiting trials for Lymphoma
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
- NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting
Other Cancer Research UK trials
Trials by the same sponsor.
- NCT04908111 — A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 · Phase 1, PHASE2 · suspended
- NCT04455815 — A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) · Phase 2 · terminated
- NCT03371485 — AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer · Phase 1 · completed
- NCT03486730 — BT1718 in Patients with Advanced Solid Tumours. · Phase 1, PHASE2 · completed
- NCT03096054 — A CR-UK Phase I Trial of LY3143921 · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00829205 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cancer Research UK
- Last refreshed: 23 August 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00829205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing